AMARAL, Carolina M.M., Kateřina CETKOVSKÁ, Ana P.A.D. GURGEL, MV CARDOSO, Bárbara S. CHAGAS, Sérgio S.L. PAIVA, Rita de Cássia Pereira d LIMA, Jacinto C. SILVA-NETO, Luiz A.F. SILVA, Maria T.C. MUNIZ, Valdir Q. BALBINO a Antonio C. FREITAS. MDM2 polymorphism associated with the development of cervical lesions in women infected with Human papillomavirus and using of oral contraceptives. Infectious Agents and Cancer. London: BioMed Central, roč. 9, č. 24, s. 1-8. ISSN 1750-9378. doi:10.1186/1750-9378-9-24. 2014.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název MDM2 polymorphism associated with the development of cervical lesions in women infected with Human papillomavirus and using of oral contraceptives
Autoři AMARAL, Carolina M.M. (76 Brazílie), Kateřina CETKOVSKÁ (203 Česká republika, garant, domácí), Ana P.A.D. GURGEL (76 Brazílie), MV CARDOSO (76 Brazílie), Bárbara S. CHAGAS (76 Brazílie), Sérgio S.L. PAIVA (76 Brazílie), Rita de Cássia Pereira d LIMA (76 Brazílie), Jacinto C. SILVA-NETO (76 Brazílie), Luiz A.F. SILVA (76 Brazílie), Maria T.C. MUNIZ (76 Brazílie), Valdir Q. BALBINO (76 Brazílie) a Antonio C. FREITAS (76 Brazílie).
Vydání Infectious Agents and Cancer, London, BioMed Central, 2014, 1750-9378.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.358
Kód RIV RIV/00216224:14110/14:00076447
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1186/1750-9378-9-24
UT WoS 000339682400002
Klíčová slova anglicky MDM2; HPV; Oral contraceptives; Cervical cancer
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 23. 1. 2015 14:49.
Anotace
Background: The MDM2 gene is the major negative regulator of p53, a tumor suppressor protein. Single nucleotide polymorphism in promoter region of MDM2 gene leads to increased expression resulting in higher levels of MDM2 protein. This event increases the attenuation of the p53 pathway. Polymorphisms in this gene can interfere in the regulation of cellular proliferation. We evaluated whether MDM2 SNP309 (rs2278744) associated or not with the use of oral contraceptive can heighten susceptibility to development of cervical lesions in women HPV infected. Methods: MDM2 SNP309 (rs2278744) was genotyped in a total of 287 patients using the PCR-RFLP technique. The results were analyzed by UNPHASED v.3.121 and SNPStats programs. Results: The three groups (SIL, LSIL and HSIL) showed no significant differences in either genotype or allelic frequencies for MDM2 polymorphisms, except when HSIL was compared with LSIL (p = 0.037; OR = 1.81). Furthermore, in the analysis of contraceptives, a significant association was found between the use of contraceptives and the MDM2 variant in the development of high-grade cervical lesions for the TG genotype (p = 0.019; OR = 2.21) when HSIL was compared with control. When HSIL was compared with LSIL (p = 0.006; OR = 2.27). Conclusion: The results of this study suggest that MDM2 SNP309 might be a good marker for assessing the progression of LSIL to HSIL. In addition, they also show that oral contraceptives alone, did not have any effect on the progression or development of cervical lesions. However, they may act synergistically with MDM2 SNP309 (rs2278744) and HPV infection in the development of cervical lesions.
VytisknoutZobrazeno: 19. 4. 2024 07:08